{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965904",
  "id": "02965904",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250704",
  "time": "0824",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250704/pdf/06lg88022kfm4w.pdf",
  "summary": "- **PANCOSIL Study Recruitment Completed**: Patient recruitment for the PANCOSIL trial (Phase 1-2 feasibility study) has concluded with 20 patients enrolled.  \n- **Key Objective**: Assessing a novel CT-guided percutaneous delivery method for the OncoSil\u2122 device, which could simplify administration and broaden adoption.  \n- **Preliminary Data Expected**: Late 2025.  \n\n*No immediate financial or capital markets impact identified; focus on clinical milestone.*",
  "usage": {
    "prompt_tokens": 1679,
    "completion_tokens": 97,
    "total_tokens": 1776,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-03T23:04:17.375926"
}